Immuno-Oncology Assays Market, By Product (Consumables and Software), By Technology (Immunoassay, PCR, NGS, Flow Cytometry, and Others), By Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others), By Application (Clinical Diagnostics and Research and Development), and By Region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Immuno-oncology is emerging as a novel approach to cancer treatment through the stimulation of the body's own immune system. It is a formidable weapon against cancer as it has the ability to harness the body's natural defenses against infection. It is method that tap into the patient's own immune system to detect and destroy cancer cells. Immuno-oncology is one of the most promising areas of research in the world of anti-cancer therapeutics.
Market Dynamics:
Increase in burden of cancer across the globe, rise in focus on the development of novel cancer treatments, increase in research and development (R&D) activities, and growing significance of immuno-oncology are some major factors expected to drive growth of the global immuno-oncology assays market over the forecast period.
For instance, in April 2021, Roche announced the launch of its Elecsys Anti-p53 immunoassay to boost in vitro quantitative determination of anti-p53 antibodies to help diagnose throat, bowel, and breast cancer. Moreover, in April 2019, Roche Diagnostics announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for identification of human epidermal growth factor receptor 2 (HER2) biomarker in breast and gastric cancers.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook